Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1975 Aug;21(2):236-43.

The inhibition of complement-dependent lymphocyte rosette formation by the sera of children with steroid-sensitive hephrotic syndrome and other renal diseases

The inhibition of complement-dependent lymphocyte rosette formation by the sera of children with steroid-sensitive hephrotic syndrome and other renal diseases

M D Smith et al. Clin Exp Immunol. 1975 Aug.

Abstract

Sera from patients with steroid-sensitive nephrotic syndrome (SSNS) in relapse, Henoch-Schonlein purpura with nephritis (HSP) and acute post-strptococcal glomerulonephritis inhibited EAC rosette formation by normal human lymphocytes; a similar effect was seen in some patients with focal glomerulosclerosis, but not in patients with congenital neophrotic syndrome. There was significantly less inhibition by sera of SSNS and HSP patients in remission. There were fewer EAC rosette-forming cells (EAC-RFC) in the blood of three patients with SSNS in relapse, suggesting that such blockade occurred in vivo. These findings, interpreted as evidence of circulating activated C3 in the sera, provide further indirect evidence of the immunopathogenesis of these diseases. Sera of healthy adults inhibited EAC rosette formation to a small extent which correclated inversely with the numbers of EAC-RFC in their blood. The EAC rosette inhibition test may be sensitive enough to detect normal variations of complement activation in healthy individuals.

PubMed Disclaimer

References

    1. Q J Med. 1960 Apr;29:235-56 - PubMed
    1. Clin Exp Immunol. 1970 Jan;6(1):109-16 - PubMed
    1. Lancet. 1959 Mar 7;1(7071):500-2 - PubMed
    1. Clin Exp Immunol. 1973 Apr;13(4):553-9 - PubMed
    1. Lancet. 1972 Aug 19;2(7773):343-8 - PubMed

Substances

LinkOut - more resources